Ortin Global Ltd

Ortin Global Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ortin Global Ltd

₹ 19.0 -0.16%
22 Nov - close price
ortinlabsindia.com BSE: 539287 NSE: ORTINGLOBE
About

Incorporated in 1986, Ortin Laboratories Ltd is engaged in the manufacturing and trading of Pharmaceuticals, Drugs and Intermediates.

Key Points

Product Portfolio:
a) Formulations:[1] Anti Diabetics, Anti Allergics, Anti Anginal & Cardio Vascular, Sedatives & Tranquillizers, Analgesics & Antipyretics Anti Helmenthetics, Anti-fungal, Anti Biotics-Quinolones, Anti Biotic-Penicillin, Chemo Therapeutics, Cephalosporins, Macrolides, Anti-ulcerants & Antacids, Anti-spasmodic, Calcium preparations, Iron preparations, Gynec, Anti -Arthritic Drugs, Protein supplements, Enzymes, Vitamins, Psychiatry, Appetizers, Anti-Retroviral
b) API Intermediates:[2] Anti retro viral, Anti Diabetics, Antifungal, Antacids & Anti ulcerant, Analgesics & Antipyretics, Anti - Biotic, Anti malarial, Fine chemicals, Grignard & alkali metal products
c) Merchant Export Trading:[3]
Company supplies pharmaceutical formulations comprising tablets, capsules, liquid orals, ear
drops, nasal drops, ointments, liquid injections, sterile dry powder injections, pharmaceutical veterinary tablets, dry syrups, sterile powder.

Website BSE NSE
  • Market Cap ₹ 15.5 Cr.
  • Current Price ₹ 19.0
  • High / Low ₹ 26.4 / 16.2
  • Stock P/E
  • Book Value ₹ 2.77
  • Dividend Yield 0.00 %
  • ROCE -40.6 %
  • ROE -91.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 6.88 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -58.3% over past five years.
  • Promoter holding is low: 1.23%
  • Company has a low return on equity of -23.4% over last 3 years.
  • Company has high debtors of 306 days.
  • Company's cost of borrowing seems high
  • Promoter holding has decreased over last 3 years: -14.4%
  • Working capital days have increased from 199 days to 341 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
2.29 1.66 2.45 2.62 0.79 1.17 1.49 1.57 0.27 0.14 0.30 0.21 0.05
2.00 1.65 2.59 2.41 1.01 0.55 1.52 1.39 1.17 2.74 3.35 0.31 0.50
Operating Profit 0.29 0.01 -0.14 0.21 -0.22 0.62 -0.03 0.18 -0.90 -2.60 -3.05 -0.10 -0.45
OPM % 12.66% 0.60% -5.71% 8.02% -27.85% 52.99% -2.01% 11.46% -333.33% -1,857.14% -1,016.67% -47.62% -900.00%
0.04 0.00 0.00 0.00 0.00 0.00 -0.03 0.00 0.00 0.00 0.00 0.00 0.00
Interest 0.19 0.19 0.24 0.10 0.09 0.10 0.12 0.11 0.15 0.14 0.08 0.00 0.02
Depreciation 0.07 -0.07 0.23 0.07 0.07 0.07 0.03 0.06 0.06 0.06 0.05 0.00 0.00
Profit before tax 0.07 -0.11 -0.61 0.04 -0.38 0.45 -0.21 0.01 -1.11 -2.80 -3.18 -0.10 -0.47
Tax % 28.57% -18.18% -24.59% 1,150.00% -121.05% 0.00% -4.76% 0.00% 1.80% -0.71% 30.19% 0.00% 0.00%
0.05 -0.09 -0.45 -0.43 0.08 0.46 -0.20 0.02 -1.12 -2.79 -4.14 -0.10 -0.47
EPS in Rs 0.06 -0.11 -0.55 -0.53 0.10 0.57 -0.25 0.02 -1.38 -3.43 -5.09 -0.12 -0.58
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
74.74 67.00 60.29 62.72 61.57 79.63 167.51 197.36 8.16 8.23 6.00 2.11 0.70
68.17 60.90 53.80 56.83 56.12 74.22 160.83 191.66 6.92 7.85 5.47 6.50 6.90
Operating Profit 6.57 6.10 6.49 5.89 5.45 5.41 6.68 5.70 1.24 0.38 0.53 -4.39 -6.20
OPM % 8.79% 9.10% 10.76% 9.39% 8.85% 6.79% 3.99% 2.89% 15.20% 4.62% 8.83% -208.06% -885.71%
0.24 0.81 0.00 0.57 0.32 0.45 0.13 0.18 0.05 0.19 0.01 -1.98 0.00
Interest 3.55 3.72 3.52 3.42 2.94 3.49 3.22 3.21 0.87 0.81 0.40 0.48 0.24
Depreciation 1.40 1.51 1.64 1.65 1.70 1.69 1.75 1.96 0.29 0.29 0.25 0.23 0.11
Profit before tax 1.86 1.68 1.33 1.39 1.13 0.68 1.84 0.71 0.13 -0.53 -0.11 -7.08 -6.55
Tax % 41.40% 29.17% 32.33% 41.01% 55.75% 0.00% 30.43% 181.69% -623.08% -24.53% -18.18% 13.56%
1.09 1.19 0.90 0.83 0.50 0.68 1.28 -0.56 0.95 -0.40 -0.09 -8.04 -7.50
EPS in Rs 0.64 0.70 0.53 0.49 0.30 0.40 0.76 -0.33 1.17 -0.49 -0.11 -9.89 -9.22
Dividend Payout % 38.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: -29%
5 Years: -58%
3 Years: -36%
TTM: -84%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -826%
Stock Price CAGR
10 Years: %
5 Years: 16%
3 Years: -12%
1 Year: -4%
Return on Equity
10 Years: -1%
5 Years: -9%
3 Years: -23%
Last Year: -92%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 16.94 16.94 16.94 16.94 16.94 16.94 16.94 16.94 8.13 8.13 8.13 8.13 8.13
Reserves 3.84 5.02 5.50 6.33 6.46 7.14 8.15 6.88 3.22 2.83 2.73 -5.31 -5.88
17.92 18.68 20.96 20.85 17.34 17.34 19.47 19.57 6.94 6.14 6.45 1.80 0.20
34.80 31.93 23.87 21.22 20.79 32.24 60.53 73.13 2.97 3.61 3.89 2.05 1.58
Total Liabilities 73.50 72.57 67.27 65.34 61.53 73.66 105.09 116.52 21.26 20.71 21.20 6.67 4.03
24.77 23.90 21.83 21.63 20.69 20.03 21.29 22.45 14.38 14.21 13.96 0.01 0.00
CWIP 0.00 0.00 0.00 0.00 0.35 0.40 0.53 0.43 0.43 0.43 0.43 0.00 0.00
Investments 0.03 0.03 0.03 0.03 0.07 0.08 0.08 0.07 0.00 0.00 0.00 0.00 0.00
48.70 48.64 45.41 43.68 40.42 53.15 83.19 93.57 6.45 6.07 6.81 6.66 4.03
Total Assets 73.50 72.57 67.27 65.34 61.53 73.66 105.09 116.52 21.26 20.71 21.20 6.67 4.03

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-1.66 -1.76 -1.38 0.52 1.94 1.56 6.52 3.30 18.03 2.15 -0.25 -4.79
-2.08 -0.02 0.22 -0.86 -1.26 -0.90 -3.27 -3.09 0.07 -0.13 0.01 12.00
4.70 0.97 1.73 0.27 -0.82 0.07 -2.89 -1.33 -9.86 -0.47 0.90 -3.49
Net Cash Flow 0.96 -0.81 0.58 -0.07 -0.14 0.73 0.37 -1.12 8.25 1.55 0.66 3.72

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 134.10 116.69 103.77 53.13 90.35 100.15 82.43 68.71 174.90 143.69 208.05 306.18
Inventory Days 102.80 162.92 192.30 148.72 158.21 152.21 100.07 117.80 169.10 136.29 279.94 4.92
Days Payable 199.45 197.95 151.09 24.82 108.10 143.09 145.12 155.80 123.82 61.88 166.89 7.87
Cash Conversion Cycle 37.45 81.66 144.97 177.04 140.45 109.28 37.38 30.70 220.17 218.10 321.10 303.23
Working Capital Days 56.94 86.07 118.60 104.81 126.92 108.68 48.94 38.38 158.79 86.93 168.51 340.78
ROCE % 14.90% 13.08% 12.07% 10.92% 9.57% 9.44% 11.77% 8.94% 3.24% 1.58% 1.80% -40.58%

Shareholding Pattern

Numbers in percentages

31 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
15.68% 15.68% 15.68% 15.68% 15.68% 21.51% 7.36% 7.37% 7.36% 1.23% 1.23% 1.23%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.25% 6.25%
84.32% 84.32% 84.32% 84.32% 84.31% 78.49% 92.63% 92.64% 92.64% 98.76% 92.53% 92.52%
No. of Shareholders 12,81912,66212,57112,44912,78112,58512,18111,83612,31412,19211,95212,165

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports